Company intelligence
Samay
Sylvee: AI-powered chest acoustics for earlier, more accurate COPD detection and remote respiratory care
About Samay
Samay develops Sylvee, an AI-enabled chest sensor and acoustic resonance platform for respiratory care. Backed by 22 patents and $7M+ in funding, Sylvee delivers >90% precision in COPD detection and enables early diagnosis, continuous remote monitoring, and biomarker discovery for millions at risk.
Verified activity
Signals from Samay
9 published signals
Presence & Recognition
Samay was featured in a lineup at the Boston event by Latinos in Bio.
Reported by Samay
Presence & Recognition
Samay participated at the European Respiratory Society Booth C1 in the Pulmonary Pavilion.
Reported by Samay
Presence & Recognition
Samay will be attending the European Respiratory Society (ERS) Congress at C1 in the Pulmonary Pavillion, right by the food trucks.
Reported by Maria Artunduaga, MD, MPH, MTM
Legal & Regulatory
Samay filed for a patent in Mexico for the product.
Reported by Samay
Presence & Recognition
Samay is presenting at LSI Europe 26 in Barcelona from September 28 to October 1.
Reported by Samay
Research & Knowledge
Samay tested Sylvee in an 8-patient pilot showing that the signal preceded exacerbation by 10 to 15 days in all 4 patients who re-exacerbated within 6 months.
Reported by Maria Artunduaga, MD, MPH, MTM
Research & Knowledge
Samay validated Sylvee in 470 participants with an AUC of 0.93 for air trapping against CT and 0.93 for obstruction against spirometry.
Reported by Maria Artunduaga, MD, MPH, MTM
Research & Knowledge
Samay built Sylvee to measure air trapping and airflow obstruction acoustically at the point of care in under five minutes without a specialist.
Reported by Maria Artunduaga, MD, MPH, MTM
Presence & Recognition
Samay will be attending the European Respiratory Society in Barcelona from September 5 to 9.
Reported by Maria Artunduaga, MD, MPH, MTM